2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Volume
41
Pagination
111 - 188
DOI
10.1093/eurheartj/ehz455
Journal
EUROPEAN HEART JOURNAL
Issue
ISSN
0195-668X
Metadata
Show full item recordAuthors
Mach, F; Baigent, C; Catapano, AL; Koskinas, KC; Casula, M; Badimon, L; Chapman, MJ; De Backer, GG; Delgado, V; Ference, BACollections
- NIHR Advanced Imaging [387]
Related items
Showing items related by title, author, creator and subject.
-
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz, GG; Szarek, M; Bittner, VA; Diaz, R; Goodman, SG; Jukema, JW; Landmesser, U; López-Jaramillo, P; Manvelian, G; Pordy, R (2021-08-03)BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum ... -
Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes
Fredrikson, GN; Anand, DV; Hopkins, D; Corder, R; Alm, R; Bengtsson, E; Shah, PK; Lahiri, A; Nilsson, J (2009-07) -
A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans.
Timpson, NJ; Walter, K; Min, JL; Tachmazidou, I; Malerba, G; Shin, S-Y; Chen, L; Futema, M; Southam, L; Iotchkova, V (2014-09-16)The analysis of rich catalogues of genetic variation from population-based sequencing provides an opportunity to screen for functional effects. Here we report a rare variant in APOC3 (rs138326449-A, minor allele frequency ...